NeuralStem Inc. Reports First Quarter Financial Results And Provides Business And Clinical Update
5/12/2014 7:44:08 AM
ROCKVILLE, Md., May 10, 2013 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) today reported its financial results for the three months ended March 31, 2013 and provided a business and clinical update.
"The Company continues to progress all of its clinical trial programs, in the U.S. and abroad, as we move into 2013. The FDA has approved our Phase II trial protocol for NSI-566/ALS, which we expect to initiate this summer.
Help employers find you! Check out all the jobs and post your resume.
comments powered by